NEW YORK (GenomeWeb News) – The National Cancer Institute plans to fund research that will use a range of 'omics technologies to develop and validate biomarkers for malignancies of the blood under two new grant programs.

NCI will use five-year R01 and two-year R21 grant mechanisms to support scientists developing genomic, proteomic, epigenomic, and transcriptomic delivery and development methods, as well as the use of standardized biospecimens for validation studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.